img

Global Pulmonary Drugs Industry Research Report, Growth Trends and Competitive Analysis 2024-2034


Published on: 2024-01-04 | No of Pages : 400 | Industry : Pharma & Healthcare

Publisher : MRA | Format : PDF

Global Pulmonary Drugs Industry Research Report, Growth Trends and Competitive Analysis 2024-2034

The pulmonary drugs are used for treating the conditions affecting lungs. The pulmonary drugs are used from treating minor illnesses such as the common cold to cure long-term disorders such asthma. These agents are available in different forms such as oral tablets, oral liquids, and injections or inhalations. Inhalations deliver the medicine directly to the lungs, which can act directly on the lung tissues, minimizing systemic side effects.
The global Pulmonary Drugs market size was US$ million in 2022 and is forecast to a readjusted size of US$ million by 2034 with a CAGR of % during the forecast period 2024-2034.
The major factors driving growth of the pulmonary drugs market include increasing incidence of chronic respiratory diseases, tobacco smoking, and government and non-government initiatives.
In terms of sales (consumption) side, this report focuses on the sales of Pulmonary Drugs by regions (Countries), company, by type and by type. from 2018 to 2024 and forecast to 2034.
The global Pulmonary Drugs market is thoroughly, accurately, and comprehensively assessed in the report with a large focus on market dynamics, market competition, regional growth, segmental analysis, and key growth strategies. Buyers of the report will have access to verified market figures, including global market size in terms of revenue and volume. As part of sales analysis, the authors of the report have provided reliable estimations and calculations for global revenue and sales by type segment of the global Pulmonary Drugs market. These figures have been provided in terms of both revenue and sales for the period 2018-2034. Additionally, the report provides accurate figures for sales by region in terms of revenue as well as volume for the same period.



By Company


Sanofi SA
Meda Pharmaceuticals
Circassia Pharmaceuticals Plc.
AstraZeneca Plc.
GlaxoSmithKline Plc.
Mallinckrodt Pharmaceuticals Plc.
Cheisi Farmaceutici S.p.A
Zambon Company S.p.A
Alaxia SAS
Merck Sharp & Dohme Limited
By Type
Inhaled Corticosteroids
Long Acting Beta-2 Agonists
Antihistamines
Vasodilators
Others
By Application
Asthma & COPD
Allergic Rhinitis
Pulmonary Arterial Hypertension
Cystic Fibrosis
Others
Sales by Region
North America
U.S.
Canada
China
APAC (excluding China)
Japan
South Korea
China Taiwan
Southeast Asia
Europe
Germany
France
U.K.
Italy
Russia
Middle East, Africa, Latin America
Brazil
Mexico
Turkey
Israel
GCC Countries

Chapter Outline


Chapter 1Introduces the report scope of the report, executive summary of different market segments (by type and by application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2Sales (consumption), revenue of Pulmonary Drugs in global, regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.
Chapter 3Detailed analysis of Pulmonary Drugs manufacturers competitive landscape, price, sales, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 4Provides the analysis of various market segments by type, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5Provides the analysis of various market segments by application, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6North America by company, by type, by application and by country, sales, and revenue for each segment.
Chapter 7Europe by company, by type, by application and by country, sales, and revenue for each segment.
Chapter 8China by company, by type and by application, sales, and revenue for each segment.
Chapter 9APAC (excluding China) by company, by type, by application and by region, sales, and revenue for each segment.
Chapter 10Middle East, Africa, and Latin America by company, by type, by application and by country, sales, and revenue for each segment.
Chapter 11Provides profiles of key manufacturers, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Pulmonary Drugs sales, revenue, price, gross margin, and recent development, etc.
Chapter 12Analysis of industrial chain, sales channel, key raw materials, distributors, and customers.
Chapter 13Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 14The main points and conclusions of the report.

Table of Content

1 Report Overview
1.1 Pulmonary Drugs Definition
1.2 Market by Type
1.2.1 Global Pulmonary Drugs Market Size Growth Rate by Type, 2018 VS 2022 VS 2034
1.2.2 Inhaled Corticosteroids
1.2.3 Long Acting Beta-2 Agonists
1.2.4 Antihistamines
1.2.5 Vasodilators
1.2.6 Others
1.3 Market Segment by Application
1.3.1 Global Pulmonary Drugs Market Size Growth Rate by Application, 2018 VS 2022 VS 2034
1.3.2 Asthma & COPD
1.3.3 Allergic Rhinitis
1.3.4 Pulmonary Arterial Hypertension
1.3.5 Cystic Fibrosis
1.3.6 Others
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Global Pulmonary Drugs Sales
2.1 Global Pulmonary Drugs Revenue Estimates and Forecasts 2018-2034
2.2 Global Pulmonary Drugs Revenue by Region: 2018 VS 2022 VS 2034
2.3 Global Pulmonary Drugs Revenue by Region
2.3.1 Global Pulmonary Drugs Revenue by Region (2018-2024)
2.3.2 Global Pulmonary Drugs Revenue by Region (2024-2034)
2.4 Global Pulmonary Drugs Sales Quantity Estimates and Forecasts 2018-2034
2.5 Global Pulmonary Drugs Sales Quantity by Region: 2018 VS 2022 VS 2034
2.6 Global Pulmonary Drugs Sales Quantity by Region
2.6.1 Global Pulmonary Drugs Sales Quantity by Region (2018-2024)
2.6.2 Global Pulmonary Drugs Sales Quantity by Region (2024-2034)
2.7 North America
2.8 Europe
2.9 China
2.10 APAC (excluding China)
2.11 Middle East, Africa and Latin America
3 Competition by Manufacturers
3.1 Global Pulmonary Drugs Sales Quantity by Manufacturers
3.1.1 Global Pulmonary Drugs Sales Quantity by Manufacturers (2018-2024)
3.1.2 Global Pulmonary Drugs Sales Quantity Share by Manufacturers (2018-2024)
3.1.3 Global Top 10 and Top 5 Companies by Pulmonary Drugs Sales in 2022
3.2 Global Pulmonary Drugs Revenue by Manufacturers
3.2.1 Global Pulmonary Drugs Revenue by Manufacturers (2018-2024)
3.2.2 Global Pulmonary Drugs Revenue Share by Manufacturers (2018-2024)
3.2.3 Global Top 10 and Top 5 Companies by Pulmonary Drugs Revenue in 2022
3.3 Global Pulmonary Drugs Sales Price by Manufacturers
3.4 Global Key Players of Pulmonary Drugs, Industry Ranking, 2021 VS 2022
3.5 Analysis of Competitive Landscape
3.5.1 Manufacturers Market Concentration Ratio (CR5 and HHI)
3.5.2 Global Pulmonary Drugs Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.6 Global Key Manufacturers of Pulmonary Drugs, Manufacturing Base Distribution and Headquarters
3.7 Global Key Manufacturers of Pulmonary Drugs, Product Offered and Application
3.8 Global Key Manufacturers of Pulmonary Drugs, Date of Enter into This Industry
3.9 Mergers & Acquisitions, Expansion Plans
4 Estimates and Forecasts by Type
4.1 Global Pulmonary Drugs Sales Quantity by Type
4.1.1 Global Pulmonary Drugs Historical Sales Quantity by Type (2018-2024)
4.1.2 Global Pulmonary Drugs Forecasted Sales Quantity by Type (2024-2034)
4.1.3 Global Pulmonary Drugs Sales Quantity Market Share by Type (2018-2034)
4.2 Global Pulmonary Drugs Revenue by Type
4.2.1 Global Pulmonary Drugs Historical Revenue by Type (2018-2024)
4.2.2 Global Pulmonary Drugs Forecasted Revenue by Type (2024-2034)
4.2.3 Global Pulmonary Drugs Revenue Market Share by Type (2018-2034)
4.3 Global Pulmonary Drugs Price by Type
4.3.1 Global Pulmonary Drugs Price by Type (2018-2024)
4.3.2 Global Pulmonary Drugs Price Forecast by Type (2024-2034)
5 Market Size by Application
5.1 Global Pulmonary Drugs Sales Quantity by Application
5.1.1 Global Pulmonary Drugs Historical Sales Quantity by Application (2018-2024)
5.1.2 Global Pulmonary Drugs Forecasted Sales Quantity by Application (2024-2034)
5.1.3 Global Pulmonary Drugs Sales Quantity Market Share by Application (2018-2034)
5.2 Global Pulmonary Drugs Revenue by Application
5.2.1 Global Pulmonary Drugs Historical Revenue by Application (2018-2024)
5.2.2 Global Pulmonary Drugs Forecasted Revenue by Application (2024-2034)
5.2.3 Global Pulmonary Drugs Revenue Market Share by Application (2018-2034)
5.3 Global Pulmonary Drugs Price by Application
5.3.1 Global Pulmonary Drugs Price by Application (2018-2024)
5.3.2 Global Pulmonary Drugs Price Forecast by Application (2024-2034)
6 North America
6.1 North America Pulmonary Drugs Sales by Company
6.1.1 North America Pulmonary Drugs Revenue by Company (2018-2024)
6.1.2 North America Pulmonary Drugs Sales Quantity by Company (2018-2024)
6.2 North America Pulmonary Drugs Market Size by Type
6.2.1 North America Pulmonary Drugs Sales Quantity by Type (2018-2034)
6.2.2 North America Pulmonary Drugs Revenue by Type (2018-2034)
6.3 North America Pulmonary Drugs Market Size by Application
6.3.1 North America Pulmonary Drugs Sales Quantity by Application (2018-2034)
6.3.2 North America Pulmonary Drugs Revenue by Application (2018-2034)
6.4 North America Pulmonary Drugs Market Size by Country
6.4.1 North America Pulmonary Drugs Revenue by Country: 2018 VS 2022 VS 2034
6.4.2 North America Pulmonary Drugs Revenue by Country (2018-2034)
6.4.3 North America Pulmonary Drugs Sales Quantity by Country (2018-2034)
6.4.4 U.S.
6.4.5 Canada
7 Europe
7.1 Europe Pulmonary Drugs Sales by Company
7.1.1 Europe Pulmonary Drugs Sales Quantity by Company (2018-2024)
7.1.2 Europe Pulmonary Drugs Revenue by Company (2018-2024)
7.2 Europe Pulmonary Drugs Market Size by Type
7.2.1 Europe Pulmonary Drugs Sales Quantity by Type (2018-2034)
7.2.2 Europe Pulmonary Drugs Revenue by Type (2018-2034)
7.3 Europe Pulmonary Drugs Market Size by Application
7.3.1 Europe Pulmonary Drugs Sales Quantity by Application (2018-2034)
7.3.2 Europe Pulmonary Drugs Revenue by Application (2018-2034)
7.4 Europe Pulmonary Drugs Market Size by Country
7.4.1 Europe Pulmonary Drugs Revenue by Country: 2018 VS 2022 VS 2034
7.4.2 Europe Pulmonary Drugs Revenue by Country (2018-2034)
7.4.3 Europe Pulmonary Drugs Sales Quantity by Country (2018-2034)
7.4.4 Germany
7.4.5 France
7.4.6 U.K.
7.4.7 Italy
7.4.8 Russia
8 China
8.1 China Pulmonary Drugs Sales by Company
8.1.1 China Pulmonary Drugs Sales Quantity by Company (2018-2024)
8.1.2 China Pulmonary Drugs Revenue by Company (2018-2024)
8.2 China Pulmonary Drugs Market Size by Type
8.2.1 China Pulmonary Drugs Sales Quantity by Type (2018-2034)
8.2.2 China Pulmonary Drugs Revenue by Type (2018-2034)
8.3 China Pulmonary Drugs Market Size by Application
8.3.1 China Pulmonary Drugs Sales Quantity by Application (2018-2034)
8.3.2 China Pulmonary Drugs Revenue by Application (2018-2034)
9 APAC (excluding China)
9.1 APAC Pulmonary Drugs Sales by Company
9.1.1 APAC Pulmonary Drugs Sales Quantity by Company (2018-2024)
9.1.2 APAC Pulmonary Drugs Revenue by Company (2018-2024)
9.2 APAC Pulmonary Drugs Market Size by Type
9.2.1 APAC Pulmonary Drugs Sales Quantity by Type (2018-2034)
9.2.2 APAC Pulmonary Drugs Revenue by Type (2018-2034)
9.3 APAC Pulmonary Drugs Market Size by Application
9.3.1 APAC Pulmonary Drugs Sales Quantity by Application (2018-2034)
9.3.2 APAC Pulmonary Drugs Revenue by Application (2018-2034)
9.4 APAC Pulmonary Drugs Market Size by Region
9.4.1 APAC Pulmonary Drugs Revenue by Region: 2018 VS 2022 VS 2034
9.4.2 APAC Pulmonary Drugs Revenue by Region (2018-2034)
9.4.3 APAC Pulmonary Drugs Sales Quantity by Region (2018-2034)
9.4.4 Japan
9.4.5 South Korea
9.4.6 China Taiwan
9.4.7 Southeast Asia
9.4.8 India
10 Middle East, Africa and Latin America
10.1 Middle East, Africa and Latin America Pulmonary Drugs Sales by Company
10.1.1 Middle East, Africa and Latin America Pulmonary Drugs Sales Quantity by Company (2018-2024)
10.1.2 Middle East, Africa and Latin America Pulmonary Drugs Revenue by Company (2018-2024)
10.2 Middle East, Africa and Latin America Pulmonary Drugs Market Size by Type
10.2.1 Middle East, Africa and Latin America Pulmonary Drugs Sales Quantity by Type (2018-2034)
10.2.2 Middle East, Africa and Latin America Pulmonary Drugs Revenue by Type (2018-2034)
10.3 Middle East, Africa and Latin America Pulmonary Drugs Market Size by Application
10.3.1 Middle East, Africa and Latin America Pulmonary Drugs Sales Quantity by Application (2018-2034)
10.3.2 Middle East, Africa and Latin America Pulmonary Drugs Revenue by Application (2018-2034)
10.4 Middle East, Africa and Latin America Pulmonary Drugs Market Size by Country
10.4.1 Middle East, Africa and Latin America Pulmonary Drugs Revenue by Country: 2018 VS 2022 VS 2034
10.4.2 Middle East, Africa and Latin America Pulmonary Drugs Revenue by Country (2018-2034)
10.4.3 Middle East, Africa and Latin America Pulmonary Drugs Sales Quantity by Country (2018-2034)
10.4.4 Brazil
10.4.5 Mexico
10.4.6 Turkey
10.4.7 Israel
10.4.8 GCC Countries
11 Company Profiles
11.1 Sanofi SA
11.1.1 Sanofi SA Company Information
11.1.2 Sanofi SA Overview
11.1.3 Sanofi SA Pulmonary Drugs Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2024)
11.1.4 Sanofi SA Pulmonary Drugs Products and Services
11.1.5 Sanofi SA Pulmonary Drugs SWOT Analysis
11.1.6 Sanofi SA Recent Developments
11.2 Meda Pharmaceuticals
11.2.1 Meda Pharmaceuticals Company Information
11.2.2 Meda Pharmaceuticals Overview
11.2.3 Meda Pharmaceuticals Pulmonary Drugs Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2024)
11.2.4 Meda Pharmaceuticals Pulmonary Drugs Products and Services
11.2.5 Meda Pharmaceuticals Pulmonary Drugs SWOT Analysis
11.2.6 Meda Pharmaceuticals Recent Developments
11.3 Circassia Pharmaceuticals Plc.
11.3.1 Circassia Pharmaceuticals Plc. Company Information
11.3.2 Circassia Pharmaceuticals Plc. Overview
11.3.3 Circassia Pharmaceuticals Plc. Pulmonary Drugs Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2024)
11.3.4 Circassia Pharmaceuticals Plc. Pulmonary Drugs Products and Services
11.3.5 Circassia Pharmaceuticals Plc. Pulmonary Drugs SWOT Analysis
11.3.6 Circassia Pharmaceuticals Plc. Recent Developments
11.4 AstraZeneca Plc.
11.4.1 AstraZeneca Plc. Company Information
11.4.2 AstraZeneca Plc. Overview
11.4.3 AstraZeneca Plc. Pulmonary Drugs Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2024)
11.4.4 AstraZeneca Plc. Pulmonary Drugs Products and Services
11.4.5 AstraZeneca Plc. Pulmonary Drugs SWOT Analysis
11.4.6 AstraZeneca Plc. Recent Developments
11.5 GlaxoSmithKline Plc.
11.5.1 GlaxoSmithKline Plc. Company Information
11.5.2 GlaxoSmithKline Plc. Overview
11.5.3 GlaxoSmithKline Plc. Pulmonary Drugs Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2024)
11.5.4 GlaxoSmithKline Plc. Pulmonary Drugs Products and Services
11.5.5 GlaxoSmithKline Plc. Pulmonary Drugs SWOT Analysis
11.5.6 GlaxoSmithKline Plc. Recent Developments
11.6 Mallinckrodt Pharmaceuticals Plc.
11.6.1 Mallinckrodt Pharmaceuticals Plc. Company Information
11.6.2 Mallinckrodt Pharmaceuticals Plc. Overview
11.6.3 Mallinckrodt Pharmaceuticals Plc. Pulmonary Drugs Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2024)
11.6.4 Mallinckrodt Pharmaceuticals Plc. Pulmonary Drugs Products and Services
11.6.5 Mallinckrodt Pharmaceuticals Plc. Pulmonary Drugs SWOT Analysis
11.6.6 Mallinckrodt Pharmaceuticals Plc. Recent Developments
11.7 Cheisi Farmaceutici S.p.A
11.7.1 Cheisi Farmaceutici S.p.A Company Information
11.7.2 Cheisi Farmaceutici S.p.A Overview
11.7.3 Cheisi Farmaceutici S.p.A Pulmonary Drugs Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2024)
11.7.4 Cheisi Farmaceutici S.p.A Pulmonary Drugs Products and Services
11.7.5 Cheisi Farmaceutici S.p.A Pulmonary Drugs SWOT Analysis
11.7.6 Cheisi Farmaceutici S.p.A Recent Developments
11.8 Zambon Company S.p.A
11.8.1 Zambon Company S.p.A Company Information
11.8.2 Zambon Company S.p.A Overview
11.8.3 Zambon Company S.p.A Pulmonary Drugs Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2024)
11.8.4 Zambon Company S.p.A Pulmonary Drugs Products and Services
11.8.5 Zambon Company S.p.A Pulmonary Drugs SWOT Analysis
11.8.6 Zambon Company S.p.A Recent Developments
11.9 Alaxia SAS
11.9.1 Alaxia SAS Company Information
11.9.2 Alaxia SAS Overview
11.9.3 Alaxia SAS Pulmonary Drugs Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2024)
11.9.4 Alaxia SAS Pulmonary Drugs Products and Services
11.9.5 Alaxia SAS Pulmonary Drugs SWOT Analysis
11.9.6 Alaxia SAS Recent Developments
11.10 Merck Sharp & Dohme Limited
11.10.1 Merck Sharp & Dohme Limited Company Information
11.10.2 Merck Sharp & Dohme Limited Overview
11.10.3 Merck Sharp & Dohme Limited Pulmonary Drugs Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2024)
11.10.4 Merck Sharp & Dohme Limited Pulmonary Drugs Products and Services
11.10.5 Merck Sharp & Dohme Limited Pulmonary Drugs SWOT Analysis
11.10.6 Merck Sharp & Dohme Limited Recent Developments
12 Value Chain and Sales Channels Analysis
12.1 Pulmonary Drugs Value Chain Analysis
12.2 Pulmonary Drugs Key Raw Materials
12.2.1 Key Raw Materials
12.2.2 Raw Materials Key Suppliers
12.3 Pulmonary Drugs Production Mode & Process
12.4 Pulmonary Drugs Sales and Marketing
12.4.1 Pulmonary Drugs Sales Channels
12.4.2 Pulmonary Drugs Distributors
12.5 Pulmonary Drugs Customers
13 Market Dynamics
13.1 Pulmonary Drugs Industry Trends
13.2 Pulmonary Drugs Market Drivers
13.3 Pulmonary Drugs Market Challenges
13.4 Pulmonary Drugs Market Restraints
14 Key Findings
15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.2 Data Source
15.2 Author Details
15.3 Disclaimer

List of Figure

List of Tables
Table 1. Global Pulmonary Drugs Market Size Growth Rate (CAGR) by Type, 2018 VS 2022 VS 2034 (US$ Million)
Table 2. Major Manufacturers of Inhaled Corticosteroids
Table 3. Major Manufacturers of Long Acting Beta-2 Agonists
Table 4. Major Manufacturers of Antihistamines
Table 5. Major Manufacturers of Vasodilators
Table 6. Major Manufacturers of Others
Table 7. Global Pulmonary Drugs Market Size Growth Rate (CAGR) by Application, 2018 VS 2022 VS 2034 (US$ Million)
Table 8. Global Pulmonary Drugs Revenue by Region: 2018 VS 2022 VS 2034 (US$ Million)
Table 9. Global Pulmonary Drugs Revenue by Region (2018-2024) & (US$ Million)
Table 10. Global Pulmonary Drugs Revenue Market Share by Region (2018-2024)
Table 11. Global Pulmonary Drugs Revenue by Region (2024-2034) & (US$ Million)
Table 12. Global Pulmonary Drugs Revenue Market Share by Region (2024-2034)
Table 13. Global Pulmonary Drugs Sales Quantity by Region: 2018 VS 2022 VS 2034 (K Units)
Table 14. Global Pulmonary Drugs Sales by Region (2018-2024) & (K Units)
Table 15. Global Pulmonary Drugs Sales Market Share by Region (2018-2024)
Table 16. Global Pulmonary Drugs Sales by Region (2024-2034) & (K Units)
Table 17. Global Pulmonary Drugs Sales Market Share by Region (2024-2034)
Table 18. Global Pulmonary Drugs Sales Quantity by Manufacturers (2018-2024) & (K Units)
Table 19. Global Pulmonary Drugs Sales Quantity Share by Manufacturers (2018-2024)
Table 20. Global Pulmonary Drugs Revenue by Manufacturers (2018-2024) & (US$ Million)
Table 21. Global Pulmonary Drugs Revenue Share by Manufacturers (2018-2024)
Table 22. Global Pulmonary Drugs Price by Manufacturers 2018-2024 (USD/Unit)
Table 23. Global Key Players of Pulmonary Drugs, Industry Ranking, 2021 VS 2022
Table 24. Global Pulmonary Drugs Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 25. Global Pulmonary Drugs by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Pulmonary Drugs as of 2022)
Table 26. Global Key Manufacturers of Pulmonary Drugs, Manufacturing Base Distribution and Headquarters
Table 27. Global Key Manufacturers of Pulmonary Drugs, Product Offered and Application
Table 28. Global Key Manufacturers of Pulmonary Drugs, Date of Enter into This Industry
Table 29. Mergers & Acquisitions, Expansion Plans
Table 30. Global Pulmonary Drugs Sales Quantity by Type (2018-2024) & (K Units)
Table 31. Global Pulmonary Drugs Sales Quantity by Type (2024-2034) & (K Units)
Table 32. Global Pulmonary Drugs Sales Quantity Share by Type (2018-2024)
Table 33. Global Pulmonary Drugs Sales Quantity Share by Type (2024-2034)
Table 34. Global Pulmonary Drugs Revenue by Type (2018-2024) & (US$ Million)
Table 35. Global Pulmonary Drugs Revenue by Type (2024-2034) & (US$ Million)
Table 36. Global Pulmonary Drugs Revenue Share by Type (2018-2024)
Table 37. Global Pulmonary Drugs Revenue Share by Type (2024-2034)
Table 38. Pulmonary Drugs Price by Type (2018-2024) & (USD/Unit)
Table 39. Global Pulmonary Drugs Price Forecast by Type (2024-2034) & (USD/Unit)
Table 40. Global Pulmonary Drugs Sales Quantity by Application (2018-2024) & (K Units)
Table 41. Global Pulmonary Drugs Sales Quantity by Application (2024-2034) & (K Units)
Table 42. Global Pulmonary Drugs Sales Quantity Share by Application (2018-2024)
Table 43. Global Pulmonary Drugs Sales Quantity Share by Application (2024-2034)
Table 44. Global Pulmonary Drugs Revenue by Application (2018-2024) & (US$ Million)
Table 45. Global Pulmonary Drugs Revenue by Application (2024-2034) & (US$ Million)
Table 46. Global Pulmonary Drugs Revenue Share by Application (2018-2024)
Table 47. Global Pulmonary Drugs Revenue Share by Application (2024-2034)
Table 48. Pulmonary Drugs Price by Application (2018-2024) & (USD/Unit)
Table 49. Global Pulmonary Drugs Price Forecast by Application (2024-2034) & (USD/Unit)
Table 50. North America Pulmonary Drugs Revenue by Company (2018-2024) & (US$ Million)
Table 51. North America Pulmonary Drugs Sales Quantity by Company (2018-2024) & (K Units)
Table 52. North America Pulmonary Drugs Sales Quantity by Type (2018-2024) & (K Units)
Table 53. North America Pulmonary Drugs Sales Quantity by Type (2024-2034) & (K Units)
Table 54. North America Pulmonary Drugs Revenue by Type (2018-2024) & (US$ Million)
Table 55. North America Pulmonary Drugs Revenue by Type (2024-2034) & (US$ Million)
Table 56. North America Pulmonary Drugs Sales Quantity by Application (2018-2024) & (K Units)
Table 57. North America Pulmonary Drugs Sales Quantity by Application (2024-2034) & (K Units)
Table 58. North America Pulmonary Drugs Revenue by Application (2018-2024) & (US$ Million)
Table 59. North America Pulmonary Drugs Revenue by Application (2024-2034) & (US$ Million)
Table 60. North America Pulmonary Drugs Revenue by Country: 2018 VS 2022 VS 2034 (US$ Million)
Table 61. North America Pulmonary Drugs Revenue by Country (2018-2024) & (US$ Million)
Table 62. North America Pulmonary Drugs Revenue by Country (2024-2034) & (US$ Million)
Table 63. North America Pulmonary Drugs Sales Quantity by Country (2018-2024) & (K Units)
Table 64. North America Pulmonary Drugs Sales Quantity by Country (2024-2034) & (K Units)
Table 65. Europe Pulmonary Drugs Sales Quantity by Company (2018-2024) & (K Units)
Table 66. Europe Pulmonary Drugs Revenue by Company (2018-2024) & (US$ Million)
Table 67. Europe Pulmonary Drugs Sales Quantity by Type (2018-2024) & (K Units)
Table 68. Europe Pulmonary Drugs Sales Quantity by Type (2024-2034) & (K Units)
Table 69. Europe Pulmonary Drugs Revenue by Type (2018-2024) & (US$ Million)
Table 70. Europe Pulmonary Drugs Revenue by Type (2024-2034) & (US$ Million)
Table 71. Europe Pulmonary Drugs Sales Quantity by Application (2018-2024) & (K Units)
Table 72. Europe Pulmonary Drugs Sales Quantity by Application (2024-2034) & (K Units)
Table 73. Europe Pulmonary Drugs Revenue by Application (2018-2024) & (US$ Million)
Table 74. Europe Pulmonary Drugs Revenue by Application (2024-2034) & (US$ Million)
Table 75. Europe Pulmonary Drugs Revenue by Country: 2018 VS 2022 VS 2034 (US$ Million)
Table 76. Europe Pulmonary Drugs Revenue by Country (2018-2024) & (US$ Million)
Table 77. Europe Pulmonary Drugs Revenue by Country (2024-2034) & (US$ Million)
Table 78. Europe Pulmonary Drugs Sales Quantity by Country (2018-2024) & (K Units)
Table 79. Europe Pulmonary Drugs Sales Quantity by Country (2024-2034) & (K Units)
Table 80. China Pulmonary Drugs Sales Quantity by Company (2018-2024) & (K Units)
Table 81. China Pulmonary Drugs Revenue by Company (2018-2024) & (US$ Million)
Table 82. China Pulmonary Drugs Sales Quantity by Type (2018-2024) & (K Units)
Table 83. China Pulmonary Drugs Sales Quantity by Type (2024-2034) & (K Units)
Table 84. China Pulmonary Drugs Revenue by Type (2018-2024) & (US$ Million)
Table 85. China Pulmonary Drugs Revenue by Type (2024-2034) & (US$ Million)
Table 86. China Pulmonary Drugs Sales Quantity by Application (2018-2024) & (K Units)
Table 87. China Pulmonary Drugs Sales Quantity by Application (2024-2034) & (K Units)
Table 88. China Pulmonary Drugs Revenue by Application (2018-2024) & (US$ Million)
Table 89. China Pulmonary Drugs Revenue by Application (2024-2034) & (US$ Million)
Table 90. APAC Pulmonary Drugs Sales Quantity by Company (2018-2024) & (K Units)
Table 91. APAC Pulmonary Drugs Revenue by Company (2018-2024) & (US$ Million)
Table 92. APAC Pulmonary Drugs Sales Quantity by Type (2018-2024) & (K Units)
Table 93. APAC Pulmonary Drugs Sales Quantity by Type (2024-2034) & (K Units)
Table 94. APAC Pulmonary Drugs Revenue by Type (2018-2024) & (US$ Million)
Table 95. APAC Pulmonary Drugs Revenue by Type (2024-2034) & (US$ Million)
Table 96. APAC Pulmonary Drugs Sales Quantity by Application (2018-2024) & (K Units)
Table 97. APAC Pulmonary Drugs Sales Quantity by Application (2024-2034) & (K Units)
Table 98. APAC Pulmonary Drugs Revenue by Application (2018-2024) & (US$ Million)
Table 99. APAC Pulmonary Drugs Revenue by Application (2024-2034) & (US$ Million)
Table 100. APAC Pulmonary Drugs Revenue by Region: 2018 VS 2022 VS 2034 (US$ Million)
Table 101. APAC Pulmonary Drugs Revenue by Region (2018-2024) & (US$ Million)
Table 102. APAC Pulmonary Drugs Revenue by Region (2024-2034) & (US$ Million)
Table 103. APAC Pulmonary Drugs Sales Quantity by Region (2018-2024) & (K Units)
Table 104. APAC Pulmonary Drugs Sales Quantity by Region (2024-2034) & (K Units)
Table 105. Middle East, Africa and Latin America Pulmonary Drugs Sales Quantity by Company (2018-2024) & (K Units)
Table 106. Middle East, Africa and Latin America Pulmonary Drugs Revenue by Company (2018-2024) & (US$ Million)
Table 107. Middle East, Africa and Latin America Pulmonary Drugs Sales Quantity by Type (2018-2024) & (K Units)
Table 108. Middle East, Africa and Latin America Pulmonary Drugs Sales Quantity by Type (2024-2034) & (K Units)
Table 109. Middle East, Africa and Latin America Pulmonary Drugs Revenue by Type (2018-2024) & (US$ Million)
Table 110. Middle East, Africa and Latin America Pulmonary Drugs Revenue by Type (2024-2034) & (US$ Million)
Table 111. Middle East, Africa and Latin America Pulmonary Drugs Sales Quantity by Application (2018-2024) & (K Units)
Table 112. Middle East, Africa and Latin America Pulmonary Drugs Sales Quantity by Application (2024-2034) & (K Units)
Table 113. Middle East, Africa and Latin America Pulmonary Drugs Revenue by Application (2018-2024) & (US$ Million)
Table 114. Middle East, Africa and Latin America Pulmonary Drugs Revenue by Application (2024-2034) & (US$ Million)
Table 115. Middle East, Africa and Latin America Pulmonary Drugs Revenue by Country: 2018 VS 2022 VS 2034 (US$ Million)
Table 116. Middle East, Africa and Latin America Pulmonary Drugs Revenue by Country (2018-2024) & (US$ Million)
Table 117. Middle East, Africa and Latin America Pulmonary Drugs Revenue by Country (2024-2034) & (US$ Million)
Table 118. Middle East, Africa and Latin America Pulmonary Drugs Sales Quantity by Country (2018-2024) & (K Units)
Table 119. Middle East, Africa and Latin America Pulmonary Drugs Sales Quantity by Country (2024-2034) & (K Units)
Table 120. Sanofi SA Company Information
Table 121. Sanofi SA Description and Overview
Table 122. Sanofi SA Pulmonary Drugs Sales Quantity (K Units), Revenue (US$ Million), Average Selling Price (ASP) (USD/Unit) and Gross Margin (2018-2024)
Table 123. Sanofi SA Pulmonary Drugs Product and Services
Table 124. Sanofi SA Pulmonary Drugs SWOT Analysis
Table 125. Sanofi SA Recent Developments
Table 126. Meda Pharmaceuticals Company Information
Table 127. Meda Pharmaceuticals Description and Overview
Table 128. Meda Pharmaceuticals Pulmonary Drugs Sales Quantity (K Units), Revenue (US$ Million), Average Selling Price (ASP) (USD/Unit) and Gross Margin (2018-2024)
Table 129. Meda Pharmaceuticals Pulmonary Drugs Product and Services
Table 130. Meda Pharmaceuticals Pulmonary Drugs SWOT Analysis
Table 131. Meda Pharmaceuticals Recent Developments
Table 132. Circassia Pharmaceuticals Plc. Company Information
Table 133. Circassia Pharmaceuticals Plc. Description and Overview
Table 134. Circassia Pharmaceuticals Plc. Pulmonary Drugs Sales Quantity (K Units), Revenue (US$ Million), Average Selling Price (ASP) (USD/Unit) and Gross Margin (2018-2024)
Table 135. Circassia Pharmaceuticals Plc. Pulmonary Drugs Product and Services
Table 136. Circassia Pharmaceuticals Plc. Pulmonary Drugs SWOT Analysis
Table 137. Circassia Pharmaceuticals Plc. Recent Developments
Table 138. AstraZeneca Plc. Company Information
Table 139. AstraZeneca Plc. Description and Overview
Table 140. AstraZeneca Plc. Pulmonary Drugs Sales Quantity (K Units), Revenue (US$ Million), Average Selling Price (ASP) (USD/Unit) and Gross Margin (2018-2024)
Table 141. AstraZeneca Plc. Pulmonary Drugs Product and Services
Table 142. AstraZeneca Plc. Pulmonary Drugs SWOT Analysis
Table 143. AstraZeneca Plc. Recent Developments
Table 144. GlaxoSmithKline Plc. Company Information
Table 145. GlaxoSmithKline Plc. Description and Overview
Table 146. GlaxoSmithKline Plc. Pulmonary Drugs Sales Quantity (K Units), Revenue (US$ Million), Average Selling Price (ASP) (USD/Unit) and Gross Margin (2018-2024)
Table 147. GlaxoSmithKline Plc. Pulmonary Drugs Product and Services
Table 148. GlaxoSmithKline Plc. Pulmonary Drugs SWOT Analysis
Table 149. GlaxoSmithKline Plc. Recent Developments
Table 150. Mallinckrodt Pharmaceuticals Plc. Company Information
Table 151. Mallinckrodt Pharmaceuticals Plc. Description and Overview
Table 152. Mallinckrodt Pharmaceuticals Plc. Pulmonary Drugs Sales Quantity (K Units), Revenue (US$ Million), Average Selling Price (ASP) (USD/Unit) and Gross Margin (2018-2024)
Table 153. Mallinckrodt Pharmaceuticals Plc. Pulmonary Drugs Product and Services
Table 154. Mallinckrodt Pharmaceuticals Plc. Pulmonary Drugs SWOT Analysis
Table 155. Mallinckrodt Pharmaceuticals Plc. Recent Developments
Table 156. Cheisi Farmaceutici S.p.A Company Information
Table 157. Cheisi Farmaceutici S.p.A Description and Overview
Table 158. Cheisi Farmaceutici S.p.A Pulmonary Drugs Sales Quantity (K Units), Revenue (US$ Million), Average Selling Price (ASP) (USD/Unit) and Gross Margin (2018-2024)
Table 159. Cheisi Farmaceutici S.p.A Pulmonary Drugs Product and Services
Table 160. Cheisi Farmaceutici S.p.A Pulmonary Drugs SWOT Analysis
Table 161. Cheisi Farmaceutici S.p.A Recent Developments
Table 162. Zambon Company S.p.A Company Information
Table 163. Zambon Company S.p.A Description and Overview
Table 164. Zambon Company S.p.A Pulmonary Drugs Sales Quantity (K Units), Revenue (US$ Million), Average Selling Price (ASP) (USD/Unit) and Gross Margin (2018-2024)
Table 165. Zambon Company S.p.A Pulmonary Drugs Product and Services
Table 166. Zambon Company S.p.A Pulmonary Drugs SWOT Analysis
Table 167. Zambon Company S.p.A Recent Developments
Table 168. Alaxia SAS Company Information
Table 169. Alaxia SAS Description and Overview
Table 170. Alaxia SAS Pulmonary Drugs Sales Quantity (K Units), Revenue (US$ Million), Average Selling Price (ASP) (USD/Unit) and Gross Margin (2018-2024)
Table 171. Alaxia SAS Pulmonary Drugs Product and Services
Table 172. Alaxia SAS Pulmonary Drugs SWOT Analysis
Table 173. Alaxia SAS Recent Developments
Table 174. Merck Sharp & Dohme Limited Company Information
Table 175. Merck Sharp & Dohme Limited Description and Overview
Table 176. Merck Sharp & Dohme Limited Pulmonary Drugs Sales Quantity (K Units), Revenue (US$ Million), Average Selling Price (ASP) (USD/Unit) and Gross Margin (2018-2024)
Table 177. Merck Sharp & Dohme Limited Pulmonary Drugs Product and Services
Table 178. Merck Sharp & Dohme Limited Pulmonary Drugs SWOT Analysis
Table 179. Merck Sharp & Dohme Limited Recent Developments
Table 180. Key Raw Materials Lists
Table 181. Raw Materials Key Suppliers Lists
Table 182. Pulmonary Drugs Distributors List
Table 183. Pulmonary Drugs Customers List
Table 184. Pulmonary Drugs Market Trends
Table 185. Pulmonary Drugs Market Drivers
Table 186. Pulmonary Drugs Market Challenges
Table 187. Pulmonary Drugs Market Restraints
Table 188. Research Programs/Design for This Report
Table 189. Key Data Information from Secondary Sources
Table 190. Key Data Information from Primary Sources
List of Figures
Figure 1. Pulmonary Drugs Product Picture
Figure 2. Global Pulmonary Drugs Market Size Growth Rate by Type, 2018 VS 2022 VS 2034 (US$ Million)
Figure 3. Global Pulmonary Drugs Market Share by Type in 2022 & 2034
Figure 4. Inhaled Corticosteroids Product Picture
Figure 5. Long Acting Beta-2 Agonists Product Picture
Figure 6. Antihistamines Product Picture
Figure 7. Vasodilators Product Picture
Figure 8. Others Product Picture
Figure 9. Global Pulmonary Drugs Market Size Growth Rate by Application, 2018 VS 2022 VS 2034 (US$ Million)
Figure 10. Global Pulmonary Drugs Market Share by Application in 2022 & 2034
Figure 11. Asthma & COPD
Figure 12. Allergic Rhinitis
Figure 13. Pulmonary Arterial Hypertension
Figure 14. Cystic Fibrosis
Figure 15. Others
Figure 16. Pulmonary Drugs Report Years Considered
Figure 17. Global Pulmonary Drugs Revenue, (US$ Million), 2018 VS 2022 VS 2034
Figure 18. Global Pulmonary Drugs Revenue 2018-2034 (US$ Million)
Figure 19. Global Pulmonary Drugs Revenue Market Share by Region in Percentage: 2022 Versus 2034
Figure 20. Global Pulmonary Drugs Sales Quantity 2018-2034 (K Units)
Figure 21. Global Pulmonary Drugs Sales Quantity Market Share by Region (2018-2024)
Figure 22. Global Pulmonary Drugs Sales Quantity Market Share by Region (2024-2034)
Figure 23. North America Pulmonary Drugs Sales Quantity YoY (2018-2034) & (K Units)
Figure 24. North America Pulmonary Drugs Revenue YoY (2018-2034) & (US$ Million)
Figure 25. Europe Pulmonary Drugs Sales Quantity YoY (2018-2034) & (K Units)
Figure 26. Europe Pulmonary Drugs Revenue YoY (2018-2034) & (US$ Million)
Figure 27. China Pulmonary Drugs Sales Quantity YoY (2018-2034) & (K Units)
Figure 28. China Pulmonary Drugs Revenue YoY (2018-2034) & (US$ Million)
Figure 29. APAC Pulmonary Drugs Sales Quantity YoY (2018-2034) & (K Units)
Figure 30. APAC Pulmonary Drugs Revenue YoY (2018-2034) & (US$ Million)
Figure 31. Middle East, Africa and Latin America Pulmonary Drugs Sales Quantity YoY (2018-2034) & (K Units)
Figure 32. Middle East, Africa and Latin America Pulmonary Drugs Revenue YoY (2018-2034) & (US$ Million)
Figure 33. The Top 10 and Top 5 Players Market Share by Pulmonary Drugs Sales Quantity in 2022
Figure 34. The Top 10 and Top 5 Players Market Share by Pulmonary Drugs Revenue in 2022
Figure 35. Pulmonary Drugs Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2018 VS 2022
Figure 36. Global Pulmonary Drugs Sales Quantity Market Share by Type (2018-2034)
Figure 37. Global Pulmonary Drugs Revenue Market Share by Type (2018-2034)
Figure 38. Global Pulmonary Drugs Sales Quantity Market Share by Application (2018-2034)
Figure 39. Global Pulmonary Drugs Revenue Market Share by Application (2018-2034)
Figure 40. North America Pulmonary Drugs Revenue Market Share by Company in 2022
Figure 41. North America Pulmonary Drugs Sales Quantity Market Share by Company in 2022
Figure 42. North America Pulmonary Drugs Sales Quantity Market Share by Type (2018-2034)
Figure 43. North America Pulmonary Drugs Revenue Market Share by Type (2018-2034)
Figure 44. North America Pulmonary Drugs Sales Quantity Market Share by Application (2018-2034)
Figure 45. North America Pulmonary Drugs Revenue Market Share by Application (2018-2034)
Figure 46. North America Pulmonary Drugs Revenue Share by Country (2018-2034)
Figure 47. North America Pulmonary Drugs Sales Quantity Share by Country (2018-2034)
Figure 48. U.S. Pulmonary Drugs Revenue (2018-2034) & (US$ Million)
Figure 49. Canada Pulmonary Drugs Revenue (2018-2034) & (US$ Million)
Figure 50. Europe Pulmonary Drugs Sales Quantity Market Share by Company in 2022
Figure 51. Europe Pulmonary Drugs Revenue Market Share by Company in 2022
Figure 52. Europe Pulmonary Drugs Sales Quantity Market Share by Type (2018-2034)
Figure 53. Europe Pulmonary Drugs Revenue Market Share by Type (2018-2034)
Figure 54. Europe Pulmonary Drugs Sales Quantity Market Share by Application (2018-2034)
Figure 55. Europe Pulmonary Drugs Revenue Market Share by Application (2018-2034)
Figure 56. Europe Pulmonary Drugs Revenue Share by Country (2018-2034)
Figure 57. Europe Pulmonary Drugs Sales Quantity Share by Country (2018-2034)
Figure 58. Germany Pulmonary Drugs Revenue (2018-2034) & (US$ Million)
Figure 59. France Pulmonary Drugs Revenue (2018-2034) & (US$ Million)
Figure 60. U.K. Pulmonary Drugs Revenue (2018-2034) & (US$ Million)
Figure 61. Italy Pulmonary Drugs Revenue (2018-2034) & (US$ Million)
Figure 62. Russia Pulmonary Drugs Revenue (2018-2034) & (US$ Million)
Figure 63. China Pulmonary Drugs Sales Quantity Market Share by Company in 2022
Figure 64. China Pulmonary Drugs Revenue Market Share by Company in 2022
Figure 65. China Pulmonary Drugs Sales Quantity Market Share by Type (2018-2034)
Figure 66. China Pulmonary Drugs Revenue Market Share by Type (2018-2034)
Figure 67. China Pulmonary Drugs Sales Quantity Market Share by Application (2018-2034)
Figure 68. China Pulmonary Drugs Revenue Market Share by Application (2018-2034)
Figure 69. APAC Pulmonary Drugs Sales Quantity Market Share by Company in 2022
Figure 70. APAC Pulmonary Drugs Revenue Market Share by Company in 2022
Figure 71. APAC Pulmonary Drugs Sales Quantity Market Share by Type (2018-2034)
Figure 72. APAC Pulmonary Drugs Revenue Market Share by Type (2018-2034)
Figure 73. APAC Pulmonary Drugs Sales Quantity Market Share by Application (2018-2034)
Figure 74. APAC Pulmonary Drugs Revenue Market Share by Application (2018-2034)
Figure 75. APAC Pulmonary Drugs Revenue Share by Region (2018-2034)
Figure 76. APAC Pulmonary Drugs Sales Quantity Share by Region (2018-2034)
Figure 77. Japan Pulmonary Drugs Revenue (2018-2034) & (US$ Million)
Figure 78. South Korea Pulmonary Drugs Revenue (2018-2034) & (US$ Million)
Figure 79. China Taiwan Pulmonary Drugs Revenue (2018-2034) & (US$ Million)
Figure 80. Southeast Asia Pulmonary Drugs Revenue (2018-2034) & (US$ Million)
Figure 81. India Pulmonary Drugs Revenue (2018-2034) & (US$ Million)
Figure 82. Middle East, Africa and Latin America Pulmonary Drugs Sales Quantity Market Share by Company in 2022
Figure 83. Middle East, Africa and Latin America Pulmonary Drugs Revenue Market Share by Company in 2022
Figure 84. Middle East, Africa and Latin America Pulmonary Drugs Sales Quantity Market Share by Type (2018-2034)
Figure 85. Middle East, Africa and Latin America Pulmonary Drugs Revenue Market Share by Type (2018-2034)
Figure 86. Middle East, Africa and Latin America Pulmonary Drugs Sales Quantity Market Share by Application (2018-2034)
Figure 87. Middle East, Africa and Latin America Pulmonary Drugs Revenue Market Share by Application (2018-2034)
Figure 88. Middle East, Africa and Latin America Pulmonary Drugs Sales Quantity Share by Country (2018-2034)
Figure 89. Middle East, Africa and Latin America Pulmonary Drugs Revenue Share by Country (2018-2034)
Figure 90. Brazil Pulmonary Drugs Revenue (2018-2034) & (US$ Million)
Figure 91. Mexico Pulmonary Drugs Revenue (2018-2034) & (US$ Million)
Figure 92. Turkey Pulmonary Drugs Revenue (2018-2034) & (US$ Million)
Figure 93. Israel Pulmonary Drugs Revenue (2018-2034) & (US$ Million)
Figure 94. GCC Countries Pulmonary Drugs Revenue (2018-2034) & (US$ Million)
Figure 95. Pulmonary Drugs Value Chain
Figure 96. Pulmonary Drugs Production Process
Figure 97. Channels of Distribution (Direct Vs Distribution)
Figure 98. Distributors Profiles
Figure 99. Bottom-up and Top-down Approaches for This Report
Figure 100. Data Triangulation
Figure 101. Key Executives Interviewed